FIELD: pharmaceutics.
SUBSTANCE: group of inventions refers to drugs, particularly to novel method of treating breast cancer, providing for parenteral administering therapeutically effective amount of (R)-4,11-dihydroxy-3-[(pyrrolidine-3-ylamino)methyl]-1H-naphto[2,3-f]indole-5,10-dione of formula I or its pharmaceutically acceptable salt.
Further, group of inventions also refers to antitumour pharmaceutical compositions for parenteral use of compounds of formula I, containing compound I, pharmacologically acceptable carrier and one or more excipients specified in co-solvents, solubilisers, filling agents, emulsifiers, preservatives, antioxidants, buffer compounds, substances for maintaining isotonicity.
EFFECT: said compositions provide effective use of the compound I, because well soluble in water pharmacologically acceptable mediums, have high stability during storage in the form of lyophilisate, and in form of aqueous solutions.
5 cl, 6 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
ORAL ANTITUMOUR DRUGS AND METHOD FOR ONCOLOGICAL DISEASES TREATMENT | 2016 |
|
RU2639479C1 |
THE USE OF CARRIMYCIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PRODUCTION OF MEDICINES FOR TREATMENT AND / OR TUMOR PREVENTION | 2018 |
|
RU2746047C1 |
METHOD OF TREATING COLON CANCER | 2012 |
|
RU2529831C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING A TUMOUR | 2018 |
|
RU2750539C2 |
USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS | 2011 |
|
RU2589695C2 |
N-{3-[3-CYCLOPROPYL-5-(2-FLUORO-4-IODOPHENYLAMINO)-6,8-DIMETHYL-2,4,7-TRIOXO-3,4,6,7-TETRAHYDRO-2H-PYRIDO[4,3-D]PYRIMIDINE-1-IL]-PHENYL}-CYCLOPROPANECARBOXAMIDE DIMETHYLSULFOXIDE SOLVATE AS MEK1/2 INHIBITOR | 2016 |
|
RU2627692C1 |
2-AMINOCHROMEN DERIVATIVES EXHIBITING ANTI-TUMOR ACTIVITY; PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2704262C1 |
CYTARABINE CONJUGATES FOR TREATING CANCER | 2016 |
|
RU2708672C1 |
ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
ANTITUMOUR ANTHRAFURANDIONE AND BASED PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2554939C1 |
Authors
Dates
2016-04-10—Published
2015-02-18—Filed